中文 | English
Return
Total: 1 , 1/1
Show Home Prev Next End page: GO
Author:(Ruifeng PEI)

1.Cost-utility analysis of tislelizumab versus sorafenib as first-line treatment for advanced unresectable hepatocellular carcinoma

Zhan SU ; Jinhui CHE ; Ruifeng PEI

China Pharmacist 2024;27(1):109-116

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 1 , 1/1 Show Home Prev Next End page: GO